First oncolytic virus approved for melanoma immunotherapy

Area of Science:

• Oncolytic virotherapy
• Cancer immunology
• Melanoma treatment

Background:

• Talimogene laherparepvec (T-VEC) is an oncolytic virus therapy.
• It is designed to treat melanoma patients with unresectable lesions.

Purpose of the Study:

• To report the US FDA approval of talimogene laherparepvec (T-VEC).
• To highlight T-VEC as the first oncolytic virus approved for cancer therapy in the US.

Main Methods:

• The US Food and Drug Administration (FDA) reviewed talimogene laherparepvec (T-VEC).
• Approval was granted for injectable, non-resectable skin and lymph node lesions in melanoma patients.

Main Results:

• Talimogene laherparepvec (T-VEC) received official FDA approval on October 27th, 2015.
• T-VEC, commercialized as Imlygic® by Amgen, Inc., is the first oncolytic virus approved in the US.

Conclusions:

• The approval of T-VEC marks a significant advancement in oncolytic virus therapy for cancer.
• This milestone provides a new therapeutic option for melanoma patients with specific lesion types.